February 10, 2019

Eluvia Drug-Eluting Stent Gains Reimbursement in Belgium

February 11, 2019—Boston Scientific Corporation announced that it has received reimbursement approval in Belgium for its Eluvia drug-eluting vascular stent system for treating superficial femoral artery and/or proximal popliteal artery lesions. The reimbursement is effective from January 1, 2019, and was obtained based on the favorable results demonstrated by Eluvia in the IMPERIAL trial, the company noted. The IMPERIAL trial compared two paclitaxel-eluting peripheral stent systems—Eluvia and Zilver PTX (Cook Medical)—and showed improved primary patency and freedom from target lesion revascularization for Eluvia at 1 year.

These data were presented at CIRSE 2019 and TCT 2019, as well as published in The Lancet.

Subscribe to our weekly newsletter.

Stay informed on the week's top stories including literature summaries, device approvals, guideline changes, and more. Plus, get our latest issues & supplements delivered to your inbox each month.

February 10, 2019

Eluvia Drug-Eluting Stent Gains Reimbursement in Belgium

Current Issue

Keep In Touch